PCM
STRO icon

Prelude Capital Management’s Sutro Biopharma STRO Stock Holding History

Prelude Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,169
Closed -$40.4K – 1547
2024
Q3 		$40.4K Sell
1,169
-1,830
-61% -$71.7K ﹤0.01% 1222
2024
Q2 		$87.9K Buy
2,999
+1,913
+176% +$75.6K 0.01% 1112
2024
Q1 		$61.3K Sell
1,086
-4,268
-80% -$189K ﹤0.01% 1243
2023
Q4 		$230K Buy
5,354
+3,460
+183% +$110K 0.02% 879
2023
Q3 		$65.7K Sell
1,894
-1,123
-37% -$48.9K ﹤0.01% 1026
2023
Q2 		$140K Sell
3,017
-62
-2% -$3.09K 0.01% 893
2023
Q1 		$142K Buy
3,079
+1,153
+60% +$73.2K 0.01% 915
2022
Q4 		$156K Buy
+1,926
New +$134K 0.01% 1011
2020
Q4 		– Sell
-70
Closed -$7K – 1951
2020
Q3 		$7K Buy
70
+30
+75% +$2.83K ﹤0.01% 1520
2020
Q2 		$3K Buy
40
+10
+33% +$960 ﹤0.01% 1794
2020
Q1 		$3K Hold
30
– – ﹤0.01% 1286
2019
Q4 		$3K Sell
30
-101
-77% -$10.4K ﹤0.01% 1817
2019
Q3 		$12K Buy
131
+40
+44% +$4.04K ﹤0.01% 1473
2019
Q2 		$10K Buy
+91
New +$10K ﹤0.01% 1400

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Prelude Capital Management's STRO Position: Q4 2024 in Review

Prelude Capital Management sold out of Sutro Biopharma (STRO) in Q4 2024, closing a stake of 1,169 shares — an estimated $40.4K sold.

Prelude Capital Management first reported a position in STRO in Q2 2019 and held it in 14 quarters. The position peaked at $230K in Q4 2023. 122 funds tracked by Wall St. Rank hold STRO as of Q4 2024.

  • Prelude Capital Management reported no remaining Sutro Biopharma position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 1,169 Sutro Biopharma shares in Q4 2024, an estimated $40.4K.
  • Prelude Capital Management first reported a position in Sutro Biopharma in Q2 2019 and held it in 14 quarters.
  • Prelude Capital Management's Sutro Biopharma position peaked at $230K in Q4 2023.
  • 122 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.